Fabrication and electrocatalytic performance of CoW11CpFe@Cu-BTC/MWCNTs-COOH modified glassy carbon electrode for simultaneous detection of dopamine and uric acid

Simultaneous detection of dopamine (DA) and uric acid (UA) is clinically important but challenging due to their similar properties, which often lead to poor sensitivity and specificity in traditional diagnostic methods. To address this, the study presents a novel hybrid nanocomposite-POM@MOF/MWCNTs-COOH-engineered for the selective and sensitive detection of both biomarkers. The material was thoroughly characterized using Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction analysis (XRD), transmission electron microscopy (TEM), inductively coupled plasma-optical emission spectrometry (ICP-OES), Brunauer-Emmett-Teller (BET) analysis, x-ray photoelectron spectroscopy (XPS), and field-emission scanning electron microscopy (FE-SEM). Electrochemical profiling was conducted using cyclic voltammetry (CV), differential pulse voltammetry (DPV), and amperometry. Under optimal conditions, the sensor demonstrated linear detection ranges of 5–100 μM and 100–550 μM for DA, with a limit of detection (LOD) of 0.16 μM, and 200–950 μM and 950–4450 μM for UA, with an LOD of 0.82 μM, as determined by DPV. These findings highlight the potential of our novel hybrid nanocomposite as a promising tool for clinical diagnostics. This innovative hybrid nanocomposite offers significant advantages over existing sensing platforms for DA and UA detection. Its unique combination of high acidity, oxygen-rich surface, and robust redox capabilities enables simultaneous detection of both analytes with enhanced sensitivity and specificity. The sensor's exceptional electrocatalytic performance positions it as a promising tool for clinical diagnostics, potentially improving healthcare outcomes through accurate biomarker detection at clinically relevant concentrations.